Clinical InvestigationCardiotrophin-1 Predicts Death or Heart Failure Following Acute Myocardial Infarction
Section snippets
Study Population
We studied 291 consecutive AMI patients admitted to the Coronary Care Unit of Leicester Royal Infirmary. The study complied with the Declaration of Helsinki and was approved by the local ethics committee; written informed consent was obtained from patients. AMI was defined at presentation with at least 2 of 3 standard criteria: appropriate symptoms, acute electrocardiograph changes of infarction (ST elevation or depression, new left bundle branch block), and a rise in troponin T above the 99th
Patient Characteristics
The demographic features of the patient population are shown in Table 1. Median length of follow-up was 336 days with a range of 0 to 645 days. Of the patients enrolled, 153 (52.6 %) received thrombolysis during the index admission. No patient was lost to follow-up. During follow-up, 27 (9.3%) patients died and 19 (6.5%) were readmitted with heart failure. Echocardiographic data were available for 252 (86.6%) of the 291 patients and done at median of 3.5 days (range 2–5) after presentation with
Discussion
Reperfusion therapy has improved mortality after MI; however the outcome of patients despite this is still poor18; for this reason, risk stratification remains important and may be useful in helping to select treatment regimes in the future. A multimarker strategy has benefits in that it uses the different pathways that are involved in the development and outcome of an AMI in the hope that complementary information can be gained.19 The aim of this study was to assess the utility of CT-1 and
Acknowledgment
The authors thank Sonja Jennings for expert technical assistance.
References (20)
- et al.
Human Cardiotrophin-1 protein and gene structure, biological and binding activities, and chromosomal localization
Cytokine
(1996) - et al.
Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series via gp130/leukemia inhibitory factor receptor-dependent pathways
J Biol Chem
(1996) - et al.
Cardiotrophin-1: biological activities and binding to the leukemia inhibitory factor receptor/gp 130 signaling complex
J Biol Chem
(1995) - et al.
Prognosis after acute myocardial infarction continues to improve in the reperfusion era in the community of Goteborg
Am Heart J
(2002) - et al.
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction
Circulation
(1998) - et al.
Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy
Proc Natl Acad Sci U S A
(1995) - et al.
Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion
Cardiovasc Res
(2002) - et al.
Cardiotrophin-1 protects the human myocardium from ischemic injury: comparison with the first and second window of protection by ischemic preconditioning
Cardiovasc Res
(2000) - et al.
Effects of cardiotrophin-1 on hemodynamics and endocrine function of the heart
Am J Physiol Heart Circ Physiol
(2000) - et al.
Plasma cardiotrophin-1 following acute myocardial infarction: relationship with left ventricular systolic dysfunction
Clin Sci
(2002)
Cited by (19)
Vascular effects of glycoprotein130 ligands - Part II: Biomarkers and therapeutic targets
2012, Vascular PharmacologyCitation Excerpt :Therefore, CT-1 may represent a diagnostic and prognostic biomarker of cardiovascular diseases (Calabro et al., 2009). CT-1 predicts death or HF following acute MI, and combined levels of CT-1 and N-terminal pro B-type natriuretic peptide (NT-proBNP) are more informative in predicting death or HF than either marker alone (Khan et al., 2006). In essential hypertension, an association between left ventricular hypertrophy and plasma concentrations of CT-1 was found.
Cardiotrophin-1 in cardiovascular regulation
2010, Advances in Clinical ChemistryCitation Excerpt :Khan et al. studied 291 patients with acute myocardial infarction, and found that plasma concentration of CT-1 at 25–48 h after the onset of chest pain was raised in patients with death or heart failure as compared with survivors. Combination of CT-1 and N-terminal BNP in a multimarker risk stratification approach is more informative at predicting death or heart failure than either marker alone [103]. Role of CT-1 in the experimental models of myocardial infarction was studied by several investigators.
Death or Heart Failure Post Acute Myocardial Infarction? The Role of Cardiac Biomarkers
2006, Journal of Cardiac FailurePlasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure
2007, European Journal of Heart FailureEndothelial dysfunction in patients with myocardial ischemia or infarction and nonobstructive coronary arteries
2021, Journal of Clinical UltrasoundCardiotrophin-1 in Patients with Acute Coronary Syndromes: Does it Have a Role?
2021, International Journal of Cardiovascular Sciences
Dr. Sohail Q. Khan is supported by a British Heart Foundation Junior Research Fellowship (FS/03/028/15486).